Gene Editing beyond CRISPR Market, 2022-2035: Focus on Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs) and Meganucleases Edited Therapies: Distribution by Type of Payment (Upfront and Milestone Payment) and Distribut
Description
Gene Editing beyond CRISPR Market, 2022-2035: Focus on Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs) and Meganucleases Edited Therapies: Distribution by Type of Payment (Upfront and Milestone Payment) and Distribution by Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035
INTRODUCTION
Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. This led to the discovery of various methods for manipulating living creatures at the genomic level, thereby, opening up a slew of new possibilities in basic and applied life sciences domain. Soon after, in the 1980s, the US FDA authorized human insulin, marketed under the brand name HUMULIN®, as the world's first genetically modified medication. With the development of various DNA modulation technologies, such as zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short palindromic repeats (CRISPR), genetic engineering and genome editing concepts have gained significant attention over the last two decades. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms.
Several medical researchers and industry stakeholders are presently engaged in exploring the potential of different gene editing technologies for basic research and development of gene editing solutions. However, the therapeutic use of these versatile genetic manipulation tools is only being investigated by selective stakeholders in the pharmaceutical and biotechnology sector. This can be attributed to the implementation of surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to the drug developers. Clinical trials of ZFNs, TALENs and meganuclease based therapeutics are primarily focused on infectious diseases and oncological disorders; however, several product candidates against certain hematological disorders, genetic disorders and neurological disorders are being evaluated in discovery and preclinical stages of development. Over time, a number of industry and non-industry players have also been validating the therapeutic applications of these technologies, which has, in turn, prompted the establishment of strategic partnerships. In fact, the growing popularity of such technologies has attracted an investment worth USD 2 billion into companies engaged in this field of research. Promising clinical results, and ongoing technical developments, coupled with the growing interest of biopharmaceutical developers, are anticipated to push the pipeline products to higher phases of development. We believe that the market is likely to evolve at a sustained pace over the next decade.
The “Gene-Editing Beyond CRISPR: Focus on ZFN, TALENS and Meganucleases Edited Therapies Market, 2021-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the ZFNs, TALENs and meganucleases based therapies market, in the mid to long term. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. This information helps us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of ZFNs, TALENs and meganucleases based therapies market and its likely evolution in the mid to long term.
Chapter 3 provides a general introduction to gene editing, evolution of genome editing tools and various types of genome editing tools. In addition, the chapter provides detailed information on the ZFNs, TALENs and meganucleases along with their structure and mechanism of action. Further, the chapter presents details on the various advantages and challenges associated with these gene editing tools and the future perspectives.
Chapter 4 provides an overview of the current market landscape of ZFNs, TALENs and meganucleases based therapies, including analyses based on several relevant parameters, such as phase of development, biological target, delivery vehicle, target indication, therapeutic area, type of therapy, cell / gene therapy, gene editing approach, delivery vehicle and route of administration. In addition, it provides details on the companies engaged in the development of ZFNs, TALENs and meganucleases based therapies, along with information on their year of establishment, company size and location of headquarters.
Chapter 5 includes detailed profiles of prominent players engaged in the development of ZFNs, TALENs and meganucleases based therapies. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
Chapter 6 provides information on completed and ongoing clinical studies of ZFNs, TALENs and meganucleases based therapies, based on different parameters, such as trial status, trial registration year, target disease indication, trial phase, study design, number of patients enrolled and type of sponsor / collaborator. In addition, the chapter highlights the active industry players and location of the trials.
Chapter 7 features a detailed review of peer-reviewed, scientific articles related to research on ZFNs, TALENs and meganucleases based therapies, on the basis of several parameters, such as year of publication, therapeutic area, emerging focus area. The chapter also highlights the top journals and top authors (in terms of number of articles published).
Chapter 8 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to ZFNs, TALENs and meganucleases based therapies, during the period, 2017- 2021, based on parameters, such as year of grant award, amount awarded, type of funding institute center, activity code, support period, prominent program officers, emerging focus areas and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded), study section, amount awarded and purpose of grant, and location of recipients.
Chapter 9 features an analysis of the partnerships that have been established in this domain, till 2021, covering instances of R&D agreements, clinical trial agreements, mergers / acquisitions, product development and commercialization agreements, licensing agreements, asset acquisitions and product development and manufacturing agreements.
Chapter 10 presents a review of the funding and investments in this domain till 2021, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding. The chapter also includes a detailed analysis of funding and investment, based on several relevant parameters.
Chapter 11 provides an insightful analysis of the patents filed / granted for ZFNs, TALENs and meganucleases till 2021, taking into consideration various parameters, such as type of patent, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed / granted), type of company, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio).
Chapter 12 presents a list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network.
Chapter 13 presents a case study on the CRISPR / Cas based therapeutics that are currently in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo), cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used.
Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of novel technologies designed for the development of ZFNs, TALENs and meganucleases based therapies till the year 2035, based on licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across A] type of payment (upfront payment and milestone payment) and [B] geography (North America, Europe, and Asia Pacific and rest of the world).
Chapter 15 is an appendix that contains list of all the figures and tables in the report.
Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
INTRODUCTION
Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. This led to the discovery of various methods for manipulating living creatures at the genomic level, thereby, opening up a slew of new possibilities in basic and applied life sciences domain. Soon after, in the 1980s, the US FDA authorized human insulin, marketed under the brand name HUMULIN®, as the world's first genetically modified medication. With the development of various DNA modulation technologies, such as zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short palindromic repeats (CRISPR), genetic engineering and genome editing concepts have gained significant attention over the last two decades. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms.
Several medical researchers and industry stakeholders are presently engaged in exploring the potential of different gene editing technologies for basic research and development of gene editing solutions. However, the therapeutic use of these versatile genetic manipulation tools is only being investigated by selective stakeholders in the pharmaceutical and biotechnology sector. This can be attributed to the implementation of surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to the drug developers. Clinical trials of ZFNs, TALENs and meganuclease based therapeutics are primarily focused on infectious diseases and oncological disorders; however, several product candidates against certain hematological disorders, genetic disorders and neurological disorders are being evaluated in discovery and preclinical stages of development. Over time, a number of industry and non-industry players have also been validating the therapeutic applications of these technologies, which has, in turn, prompted the establishment of strategic partnerships. In fact, the growing popularity of such technologies has attracted an investment worth USD 2 billion into companies engaged in this field of research. Promising clinical results, and ongoing technical developments, coupled with the growing interest of biopharmaceutical developers, are anticipated to push the pipeline products to higher phases of development. We believe that the market is likely to evolve at a sustained pace over the next decade.
The “Gene-Editing Beyond CRISPR: Focus on ZFN, TALENS and Meganucleases Edited Therapies Market, 2021-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the ZFNs, TALENs and meganucleases based therapies market, in the mid to long term. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
- A detailed assessment of the current market landscape of ZFNs based therapies, based on several relevant parameters, such as phase of development (clinical and preclinical), biological target (BCL 11A, C9ORF72, CD 19, HLA-A2, HTT gene, MAPT, SNCA gene, VEGF-A, HPV16/E7 and HPV18/E7), delivery vehicle (non-viral and naked plasmid), target indication, therapeutic area (blood disorders, infectious diseases, neurological disorders, oncological disorders and others) and type of therapy (in-vivo and ex-vivo). In addition, it provides details on the companies engaged in the development of ZFNs based therapies, along with information on their year of establishment, location of headquarters and company size.
A detailed assessment of the current market landscape of TALENs based therapies, based on several relevant parameters, such as phase of development (clinical and preclinical), target indication, type of cells (T Cells, NK Cells, HPV positive and B Cells), biological target (iNK, CD19, BCMA, TCR-α/CD52, CD22, CD38, CS1, GPCR, HPV18/E7, HPV16/E6, HPV16/E7 and HPV18/E6), cell / gene therapy (NK-Cell Therapy, T-Cell Therapy and CAR-T), type of therapy (in-vivo and ex-vivo), gene editing approach (insertion and deletion) and route of administration (intravenous, topical and intravaginal). In addition, it provides details on the companies engaged in the development of TALEN based therapies, along with information on their year of establishment, company size and location of headquarters.
A detailed assessment of the current market landscape of Meganucleases based therapies, based on several relevant parameters, such as phase of development (clinical and preclinical), gene editing approach, delivery vehicle (AAV9 and lentiviral), therapeutic area(s) (genetic disorders, liver disorders, kidney disorders, rare disorders, ocular disorders and oncological disorders), route of administration, type of cells, type of therapy and biological target(s) (HA01, TTR, PCSK9 and ApoC3). In addition, it provides details on the companies engaged in the development of meganucleases based therapies, along with information on their year of establishment, company size and location of headquarters.
Detailed profiles of prominent players engaged in the development of ZFNs, TALENs and meganucleases based therapies. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
A detailed analysis of completed and ongoing clinical trials of various ZFNs, TALENs and meganucleases based therapies, based on different parameters, such as trial status, trial registration year, target disease indication, trial phase, study design, number of patients enrolled and type of sponsor / collaborator. In addition, the chapter highlights the active industry players and location of the trials.
A detailed review of around 1,250 peer-reviewed, scientific articles related to research on ZFNs, TALENs and meganucleases based therapies on the basis of several parameters, such as year of publication, therapeutic area, emerging focus area. The chapter also highlights the top journals and top authors (in terms of number of articles published).
An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to ZFNs, TALENs and meganucleases based therapies, during the period, 2017-2021, based on parameters, such as year of grant award, amount awarded, type of funding institute center, activity code, support period, prominent program officers, emerging focus areas and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded), study section, amount awarded and purpose of grant, and location of recipients.
An analysis of the partnerships that have been established in this domain till 2021, covering instances of R&D agreements, clinical trial agreements, mergers / acquisitions, product development and commercialization agreements, licensing agreements, asset acquisitions and product development and manufacturing agreements.
A detailed analysis of the various investments made till 2021, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding in the companies focused on the development of therapies based on ZFNs, TALENs and meganucleases.
An insightful analysis of the patents filed / granted for ZFNs, TALENs and meganucleases till 2021, taking into consideration various parameters, such as type of patent, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, type of company, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio).
A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network.
A case study on the CRISPR / Cas based therapies that are currently in different stages of development. The chapter features a detailed analysis of pipeline molecules, based on various parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo), cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. This information helps us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
- Who are the players engaged in the development of gene editing therapies beyond CRISPR?
Which are the key drugs being developed across early and late stages of development?
Which companies are actively involved in conducting clinical trials for ZFNs, TALENs and meganucleases based therapies?
What is the focus of various publications related to ZFNs, TALENs and meganucleases based therapies?
Which are the leading administering institute centers supporting the research related to gene editing market beyond CRISPR?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the trend of capital investments in the gene editing beyond CRISPR market?
How has the intellectual property landscape in this market evolved over the years?
How is the current and future opportunity, related to ZFNs, TALENs and meganucleases based therapies, likely to be distributed across key market segments?
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of ZFNs, TALENs and meganucleases based therapies market and its likely evolution in the mid to long term.
Chapter 3 provides a general introduction to gene editing, evolution of genome editing tools and various types of genome editing tools. In addition, the chapter provides detailed information on the ZFNs, TALENs and meganucleases along with their structure and mechanism of action. Further, the chapter presents details on the various advantages and challenges associated with these gene editing tools and the future perspectives.
Chapter 4 provides an overview of the current market landscape of ZFNs, TALENs and meganucleases based therapies, including analyses based on several relevant parameters, such as phase of development, biological target, delivery vehicle, target indication, therapeutic area, type of therapy, cell / gene therapy, gene editing approach, delivery vehicle and route of administration. In addition, it provides details on the companies engaged in the development of ZFNs, TALENs and meganucleases based therapies, along with information on their year of establishment, company size and location of headquarters.
Chapter 5 includes detailed profiles of prominent players engaged in the development of ZFNs, TALENs and meganucleases based therapies. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
Chapter 6 provides information on completed and ongoing clinical studies of ZFNs, TALENs and meganucleases based therapies, based on different parameters, such as trial status, trial registration year, target disease indication, trial phase, study design, number of patients enrolled and type of sponsor / collaborator. In addition, the chapter highlights the active industry players and location of the trials.
Chapter 7 features a detailed review of peer-reviewed, scientific articles related to research on ZFNs, TALENs and meganucleases based therapies, on the basis of several parameters, such as year of publication, therapeutic area, emerging focus area. The chapter also highlights the top journals and top authors (in terms of number of articles published).
Chapter 8 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to ZFNs, TALENs and meganucleases based therapies, during the period, 2017- 2021, based on parameters, such as year of grant award, amount awarded, type of funding institute center, activity code, support period, prominent program officers, emerging focus areas and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded), study section, amount awarded and purpose of grant, and location of recipients.
Chapter 9 features an analysis of the partnerships that have been established in this domain, till 2021, covering instances of R&D agreements, clinical trial agreements, mergers / acquisitions, product development and commercialization agreements, licensing agreements, asset acquisitions and product development and manufacturing agreements.
Chapter 10 presents a review of the funding and investments in this domain till 2021, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding. The chapter also includes a detailed analysis of funding and investment, based on several relevant parameters.
Chapter 11 provides an insightful analysis of the patents filed / granted for ZFNs, TALENs and meganucleases till 2021, taking into consideration various parameters, such as type of patent, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed / granted), type of company, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio).
Chapter 12 presents a list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network.
Chapter 13 presents a case study on the CRISPR / Cas based therapeutics that are currently in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo), cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used.
Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of novel technologies designed for the development of ZFNs, TALENs and meganucleases based therapies till the year 2035, based on licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across A] type of payment (upfront payment and milestone payment) and [B] geography (North America, Europe, and Asia Pacific and rest of the world).
Chapter 15 is an appendix that contains list of all the figures and tables in the report.
Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Table of Contents
151 Pages
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Overview of Genome Editing
- 3.2. Evolution of Genome Editing Tools
- 3.3. Types of Genomes Editing Tools
- 3.4. Zinc-finger nucleases (ZFNs): An Overview
- 3.4.1. Structure of ZFNs
- 3.4.2. Mechanism of Action
- 3.5. Transcription activator-like effector nucleases (TALENs): An Overview
- 3.5.1. Structure of TALENs
- 3.5.2. Mechanism of Action
- 3.6. Meganucleases: An Overview
- 3.6.1. Structure of Meganucleases
- 3.6.2. Mechanism of Action
- 3.7. Genome Editing Tools: Advantages and Disadvantages
- 3.8. Future Perspectives
- 4. ZFNS, TALENS AND MEGANUCLEASES BASED THERAPEUTICS: MARKET LANDSCAPE
- 4.1. Pipeline Review: ZFNs
- 4.1.1. Analysis by Phase of Development
- 4.1.2. Analysis by Biological Target(s)
- 4.1.3. Analysis by Delivery Vehicle
- 4.1.4. Analysis by Target Indication(s)
- 4.1.5. Analysis by Therapeutic Area
- 4.1.6. Analysis by Type of Therapy
- 4.2. Pipeline Review: TALENS
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Target Indication(s)
- 4.2.3. Analysis by Type of Cells
- 4.2.4. Analysis by Biological Target(s) and Developer
- 4.2.5. Analysis by Cell / Gene Therapy
- 4.2.6. Analysis by Type of Therapy
- 4.2.7. Analysis by Gene Editing Approach
- 4.2.8. Analysis by Route of Administration
- 4.3. Pipeline Review: Meganucleases
- 4.3.1. Analysis by Phase of Development
- 4.3.2. Analysis by Gene Editing Approach
- 4.3.3. Analysis by Delivery Vehicle
- 4.3.4. Analysis by Therapeutic Area
- 4.3.5. Analysis by Route of Administration
- 4.3.6. Analysis by Type of Cells
- 4.3.7. Analysis by Type of Therapy
- 4.3.8. Analysis by Biological Target(s)
- 4.4. Non-CRISPR based Gene Editing Therapies: Developer Landscape
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Location of Headquarters
- 4.4.3. Analysis by Geographical Region
- 4.4.4. Analysis by Company Size
- 4.4.5. Analysis by Type of Player
- 4.4.6. Analysis by Gene Editing Technologies
- 5. COMPANY PROFILES
- 5.1. Allogene Therapeutics
- 5.1.1. Company Overview
- 5.1.2. Drug Portfolio
- 5.1.3. Recent Developments and Future Outlook
- 5.2. Bluebird Bio
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Drug Portfolio
- 5.2.4. Recent Developments and Future Outlook
- 5.3. Cellectis
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Drug Portfolio
- 5.3.4. Recent Developments and Future Outlook
- 5.4. Cytovia Therapeutics
- 5.4.1. Company Overview
- 5.4.2. Drug Portfolio
- 5.4.3. Recent Developments and Future Outlook
- 5.5. Iovance Therapeutics
- 5.5.1. Company Overview
- 5.5.2. Drug Portfolio
- 5.5.3. Recent Developments and Future Outlook
- 5.6. Precision Biosciences
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Drug Portfolio
- 5.6.4. Recent Developments and Future Outlook
- 5.7. Sangamo Therapeutics
- 5.7.1. Company Overview
- 5.7.2. Financial Information
- 5.7.3. Drug Portfolio
- 5.7.4. Recent Developments and Future Outlook
- 6. CLINICAL TRIALS ANALYSIS
- 6.1. Analysis Methodology and Key Parameters
- 6.2. List of Clinical Trials focused on ZFN, TALEN and Meganuclease edited Therapies
- 6.2.1. Analysis by Trial Status
- 6.2.2. Analysis by Trial Registration Year
- 6.2.3. Analysis by Target Disease Indication
- 6.2.4. Analysis by Trial Phase
- 6.2.5. Analysis by Study Design
- 6.2.6. Year-wise Trend of Completed and Recruiting Trials
- 6.2.7. Analysis by Phase and Patient Enrollment
- 6.2.8. Analysis by Type of Sponsor
- 6.2.9. Analysis by Patient Enrollment
- 6.2.10. Word Cloud Analysis: Emerging Focus Areas
- 6.2.11. Most Active Players: Analysis by Number of Registered Trials
- 6.2.12. Analysis by Trial Location
- 7. PUBLICATION ANALYSIS
- 7.1. Analysis Methodology and Key Parameters
- 7.2. List of Publications focused on ZFN, TALEN and Meganuclease edited Therapies
- 7.3. Publication Analysis: ZFNs
- 7.3.1. Analysis by Year of Publication
- 7.3.2. Analysis by Therapeutic Area
- 7.3.3. ZFNs: Emerging Focus Areas
- 7.3.4. Top Journals: Analysis by Number of Publications
- 7.3.5. Top Authors: Analysis by Number of Publications
- 7.4. Publication Analysis: TALENs
- 7.4.1. Analysis by Year of Publication
- 7.4.2. Analysis by Therapeutic Area
- 7.4.3. TALENs: Emerging Focus Areas
- 7.4.4. Top Journals: Analysis by Number of Publications
- 7.4.5. Top Authors: Analysis by Number of Publications
- 7.4. Publication Analysis: Meganucleases
- 7.4.1. Analysis by Year of Publication
- 7.4.2. Meganucleases: Emerging Focus Areas
- 7.4.3. Top Journals: Analysis by Number of Publications
- 7.4.4. Top Authors: Analysis by Number of Publications
- 8. ACADEMIC GRANTS ANALYSIS
- 8.1. Analysis Methodology and Key Parameters
- 8.2. List of Academic Grants focused on ZFN, TALEN and Meganuclease edited Therapies
- 8.3. Analysis by Year of Grant Award
- 8.4. Analysis by Amount Awarded
- 8.5. Analysis by Type of Funding Institute Center
- 8.6. Analysis by Activity Code
- 8.7. Analysis by Support Period
- 8.8. Prominent Program Officers: Analysis by Number of Grants
- 8.9. Word Cloud: Emerging Focus Areas
- 8.9. Analysis by Type of Grant Application
- 8.10. Analysis by Funding Institute Center and Support Period
- 8.11. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
- 8.12. Popular Type of Recipient Organization: Analysis by Number of Grants
- 8.14. Popular Type of Recipient Organization: Analysis by Amount Awarded
- 8.15. Popular NIH Departments: Analysis by Number of Grants
- 8.16. Analysis by Study Section
- 8.17. Analysis by Purpose of Grant
- 8.18. Analysis by Amount Awarded and Purpose of Grant
- 8.19. Analysis by Location of Recipients
- 9. PARTNERSHIPS AND COLLABORATIONS
- 9.1. List of Partnerships and Collaborations focused on ZFNs, TALENs and Meganucleases editing Therapies
- 9.2. Analysis by Year of Partnership
- 9.3. Analysis by Type of Partnership
- 9.4. Analysis by Year and Type of Partnership
- 9.5. Analysis by Type of Technology
- 9.6. Spider Web Analysis: Type of Technology and Type of Agreement
- 9.7. Analysis by Type of Partner
- 9.8. Active Partners
- 9.9. Analysis by Year and Type of Partner
- 9.10. Analysis by Target Disease Indication
- 9.11. Analysis by Therapeutic Area
- 9.12. Most Active Players: Analysis by Number of Partnerships
- 9.13. Licensing Deals: Analysis by Upfront and Milestone Payment
- 9.14. Analysis by Technology and Licensing Amount
- 9.15. Geographical Distribution
- 9.16. Intercontinental and Intracontinental Agreements
- 10. FUNDING AND INVESTMENT ANALYSIS
- 10.1. Gene Editing Therapies- Focus on ZFNs, TALENs and Meganucleases: List of Funding Instances
- 10.2. Analysis by Year of Funding
- 10.3. Analysis by Amount Invested
- 10.4. Analysis by Type of Funding
- 10.5. Analysis by Year, Type of Funding and Amount Invested
- 10.6. Analysis by Type of Funding and Amount Invested
- 10.7. Industry Players: Analysis by Type of Funding
- 10.8 Analysis by Geographical Regions
- 10.9. Most Active Players: Analysis by Number of Funding Instances
- 10.8. Most Active Players: Analysis by Amount Invested
- 10.9. Key Investors: Analysis by Number of Funding Instances
- 10.10. Analysis of Amount Invested by Technology
- 10.11. Analysis by Amount Invested by Therapeutic Area
- 11. PATENT ANALYSIS
- 11.1. Analysis Methodology and Key Parameters
- 11.2. Patent Analysis: ZFNs
- 11.2.1. Analysis by Type of Patent
- 11.2.2. Analysis by Publication Year
- 11.2.3. Analysis by Type of Patent and Publication Year
- 11.2.4. Analysis by Issuing Authority / Patent Offices Involved
- 11.2.5. Analysis by CPC Symbols
- 11.2.6. Word Cloud: Emerging Focus Areas
- 11.2.7. Analysis by Type of Organization
- 11.2.8. Leading Industry Players: Analysis by Number of Patents
- 11.2.9. Analysis by Patent Age, 2001-2021
- 11.2.10. ZFNs: Benchmarking Patent Analysis
- 11.2.11. ZFNs: Patent Valuation Analysis
- 11.3. Patent Analysis: TALENs
- 11.3.1. Analysis by Type of Patent
- 11.3.2. Analysis by Publication Year
- 11.3.3. Analysis by Type of Patent and Publication Year
- 11.3.4. Analysis by Issuing Authority / Patent Offices Involved
- 11.3.5. Analysis by CPC Symbols
- 11.3.6. Word Cloud Analysis: Emerging Focus Areas
- 11.3.7. Analysis by Type of Organization
- 11.3.8. Leading Industry Players: Analysis by Number of Patents
- 11.3.9. Analysis by Patent Age, 2001-2021
- 11.3.10. TALENs: Benchmarking Patent Analysis
- 11.3.11. TALENs: Patent Valuation Analysis
- 11.4. Patent Analysis: Meganucleases
- 11.4.1. Analysis by Type of Patent
- 11.4.2. Analysis by Publication Year
- 11.4.3. Analysis by Type of Patent and Publication Year
- 11.4.4. Analysis by Issuing Authority / Patent Offices Involved
- 11.4.5. Analysis by CPC Symbols
- 11.4.6. Word Cloud Analysis: Emerging Focus Areas
- 11.4.7. Analysis by Type of Organization
- 11.4.8. Leading Industry Players: Analysis by Number of Patents
- 11.4.9. Analysis by Patent Age, 2001-2021
- 11.4.10. Meganucleases: Benchmarking Patent Analysis
- 11.4.11. Meganucleases: Patent Valuation Analysis
- 12. KEY INSIGHTS ON KOLs
- 12.1. Analysis Methodology
- 12.2. Key Parameters / Assumptions
- 12.3. Analysis by Type of Organization
- 12.4. Regional Analysis
- 12.5. Analysis by Location of Headquarters
- 12.6. Analysis by Current Organization
- 12.7. Leading KOLs by Roots Analysis Proprietary Scores
- 12.8. Key Insights on KOLs
- 13. CASE STUDY: CRISPR / CAS BASED THERAPEUTICS
- 13.1. CRISPR / Cas based Therapeutics: Clinical Pipeline
- 13.1.1. Analysis by Therapeutic Approach (In vivo / Ex vivo)
- 13.1.2. Analysis by Cell Source
- 13.1.3. Analysis by Cell Type
- 13.1.4. Analysis by Target Gene
- 13.1.5. Analysis by Delivery Vehicle Used
- 13.2. CRISPR / Cas Based Therapeutics: Discovery and Preclinical Pipeline
- 13.2.1. Analysis by Phase of Development
- 13.2.2. Analysis by Therapeutic Area
- 13.2.3. Analysis by Technology Used
- 13.2.4. Analysis by Therapeutic Approach (In vivo/Ex vivo)
- 13.2.5. Analysis by Delivery Vehicle Used
- 13.2.6. Most Active Players: Analysis by Number of Drugs
- 13.3. CRISPR / Cas based Therapeutics: Developer Landscape
- 13.3.1. Analysis by Year of Establishment
- 13.3.2. Analysis by Company Size
- 13.3.3. Analysis by Geographical Location
- 13.3.4. Logo Landscape: Analysis by Size and Phase of Development of CRISPR based Therapeutics
- 13.3.5. Initiatives by Big Pharma Players
- 14. MARKET SIZING AND OPPORTUNITY ANALYSIS
- 14.1. Forecast Methodology and Key Assumptions
- 14.2. Gene Editing Therapeutics and Technologies, Focus on ZFNs, TALENs and Meganucleases: Information on Licensing Deals
- 14.3. Global ZFNs, TALENs and Meganucleases based Therapeutics and Technologies Market, 2021-2035
- 14.4. Global ZFNs, TALENs and Meganucleases based Therapeutics and Technologies Market, 2021-2035: Distribution by Region
- 14.4.1. ZFNs, TALENs and Meganucleases based Therapeutics and Technologies Market in North America, 2021-2035
- 14.4.2. ZFNs, TALENs and Meganucleases based Therapeutics and Technologies Market in Europe, 2021-2035
- 14.4.3. ZFNs, TALENs and Meganucleases based Therapeutics and Technologies Market in Asia-Pacific and rest of the world, 2021-2035
- 15. APPNEDIX 1: LIST OF FIGURES AND TABLES
- 16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 3.1 Evolution of Genome Editing Tools
- Figure 3.2 Types of Genomes Editing Tools
- Figure 3.3 Structure of ZFNs
- Figure 3.4 Mechanism of Action of ZFNs
- Figure 3.5 Structure of TALENs
- Figure 3.6 Mechanism of Action of TALENs
- Figure 3.7 Structure of Meganucleases
- Figure 3.8 Mechanism of Action of Meganucleases
- Figure 3.9 Genome Editing Tools: Advantages and Disadvantages
- Figure 3.10 Future Perspectives
- Figure 4.1 ZFNs based Therapeutics: Distribution by Phase of Development
- Figure 4.2 ZFNs based Therapeutics: Distribution by Biological Target(s)
- Figure 4.3 ZFNs based Therapeutics: Distribution by Delivery Vehicle
- Figure 4.4 ZFNs based Therapeutics: Distribution by Target Indication(s)
- Figure 4.5 ZFNs based Therapeutics: Distribution by Therapeutic Area
- Figure 4.6 ZFNs based Therapeutics: Distribution by Type of Therapy
- Figure 4.7 TALENs based Therapeutics: Distribution by Phase of Development
- Figure 4.8 TALENs based Therapeutics: Distribution by Target Indication(s)
- Figure 4.9 TALENs based Therapeutics: Distribution by Type of Cells
- Figure 4.10 TALENs based Therapeutics: Distribution by Biological Target(s) and Developer
- Figure 4.11 TALENs based Therapeutics: Distribution by Cell / Gene Therapy
- Figure 4.12 TALENs based Therapeutics: Distribution by Type of Therapy
- Figure 4.13 TALENs based Therapeutics: Distribution by Gene Editing Approach
- Figure 4.14 TALENs based Therapeutics: Distribution by Route of Administration
- Figure 4.15 Meganucleases based Therapeutics: Distribution by Phase of Development
- Figure 4.16 Meganucleases based Therapeutics: Distribution by Gene Editing Approach
- Figure 4.17 Meganucleases based Therapeutics: Distribution by Delivery Vehicle
- Figure 4.18 Meganucleases based Therapeutics: Distribution by Therapeutic Area
- Figure 4.19 Meganucleases based Therapeutics: Distribution by Route of Administration
- Figure 4.20 Meganucleases based Therapeutics: Distribution by Type of Cells
- Figure 4.21 Meganucleases based Therapeutics: Distribution by Type of Therapy
- Figure 4.22 Meganucleases based Therapeutics: Distribution by Biological Target(s)
- Figure 4.23 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Year of Establishment
- Figure 4.24 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Location of Headquarters
- Figure 4.25 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Geographical Region
- Figure 4.26 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Company Size
- Figure 4.27 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Type of Player
- Figure 4.28 Non-CRISPR based Gene Editing Therapies: Distribution of Developers by Gene Editing Technologies
- Figure 5.1 Bluebird Bio: Financial Information
- Figure 5.2 Cellectis: Financial Information
- Figure 5.3 Precision Biosciences: Financial Information
- Figure 5.4 Sangamo Therapeutics: Financial Information
- Figure 6.1 Clinical Trials Analysis: Distribution by Trial Status
- Figure 6.2 Clinical Trials Analysis: Distribution by Trial Registration Year
- Figure 6.3 Clinical Trials Analysis: Distribution by Target Disease Indication
- Figure 6.4 Clinical Trials Analysis: Distribution by Trial Phase
- Figure 6.5 Clinical Trials Analysis: Distribution by Study Design
- Figure 6.6 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
- Figure 6.7 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
- Figure 6.8 Clinical Trials Analysis: Distribution by Type of Sponsor
- Figure 6.9 Clinical Trials Analysis: Distribution by Patient Enrollment
- Figure 6.10 Clinical Trials Analysis: Distribution by Emerging Focus Areas
- Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
- Figure 6.12 Clinical Trial Analysis: Distribution by Trial Location
- Figure 7.1 Publication Analysis for ZFNs: Distribution by Year of Publication
- Figure 7.2 Publication Analysis for ZFNs: Distribution by Therapeutic Area
- Figure 7.3 Publication Analysis for ZFNs: Emerging Focus Areas
- Figure 7.4 Top Journals: Distribution by Number of Publications for ZFNs
- Figure 7.5 Top Authors: Distribution by Number of Publications for ZFNs
- Figure 7.6 Publication Analysis for TALENs: Distribution by Year of Publication
- Figure 7.7 Publication Analysis for TALENs: Distribution by Therapeutic Area
- Figure 7.8 Publication Analysis for TALENs: Emerging Focus Areas
- Figure 7.9 Top Journals: Distribution by Number of Publications for TALENs
- Figure 7.10 Top Authors: Distribution by Number of Publications for TALENs
- Figure 7.11 Publication Analysis for Meganucleases: Distribution by Year of Publication
- Figure 7.12 Publication Analysis for Meganucleases: Emerging Focus Areas
- Figure 7.13 Top Journals: Distribution by Number of Publications for Meganucleases
- Figure 7.14 Top Authors: Distribution by Number of Publications for Meganucleases
- Figure 8.1 Academic Grants Analysis: Distribution by Year of Grant Awarded
- Figure 8.2 Academic Grants Analysis: Distribution by Amount Awarded
- Figure 8.3 Academic Grants Analysis: Distribution by Type of Funding Institute Center
- Figure 8.4 Academic Grants Analysis: Distribution by Activity Code
- Figure 8.5 Academic Grants Analysis: Distribution by Support Period
- Figure 8.6 Prominent Program Officers: Distribution by Number of Grants
- Figure 8.7 Word Cloud: Emerging Focus Areas
- Figure 8.8 Academic Grants Analysis: Distribution by Type of Grant Application
- Figure 8.9 Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
- Figure 8.10 Popular Recipient Organizations: Distribution by Number of Grants and Amount Awarded
- Figure 8.11 Popular Type of Recipient Organization: Distribution by Number of Grants
- Figure 8.12 Popular Type of Recipient Organization: Distribution by Amount Awarded
- Figure 8.13 Popular NIH Departments: Distribution by Number of Grants
- Figure 8.14 Academic Grants Analysis: Distribution by Study Section
- Figure 8.15 Academic Grants Analysis: Distribution by Purpose of Grant
- Figure 8.16 Academic Grants Analysis: Distribution by Amount Awarded and Purpose of Grant
- Figure 8.17 Academic Grants Analysis: Distribution by Location of Recipients
- Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
- Figure 9.2 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Figure 9.3 Partnerships and Collaborations: Distribution by Type of Technology
- Figure 9.4 Spider Web Analysis: Distribution by Type of Technology and Type of Agreement
- Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
- Figure 9.6 Active Partners: Distribution by Number of Partnerships
- Figure 9.7 Partnerships and Collaborations: Distribution by Year and Type of Partner
- Figure 9.8 Partnerships and Collaborations: Distribution by Target Disease Indication
- Figure 9.9 Partnerships and Collaborations: Distribution by Therapeutic Area
- Figure 9.10 Most Active Players: Distribution by Number of Partnerships
- Figure 9.11 Licensing Deals: Distribution by Upfront and Milestone Payment
- Figure 9.12 Partnerships and Collaborations: Distribution by Technology and Licensing Amount
- Figure 9.13 Partnerships and Collaborations: Geographical Distribution
- Figure 9.14 Intercontinental and Intracontinental Agreements
- Figure 10.1 Funding and Investments: Distribution by Year of Funding
- Figure 10.2 Funding and Investments: Distribution by Amount Invested
- Figure 10.3 Funding and Investments: Distribution by Type of Funding
- Figure 10.4 Funding and Investments: Distribution by Year, Type of Funding and Amount Invested
- Figure 10.5 Funding and Investments: Distribution by Type of Funding and Amount Invested
- Figure 10.6 Industry Players: Distribution by Type of Funding
- Figure 10.7 Funding and Investments: Distribution by Geographical Regions
- Figure 10.8 Most Active Players: Distribution by Number of Funding Instances
- Figure 10.9 Most Active Players: Distribution by Amount Invested
- Figure 10.10 Key Investors: Distribution by Number of Funding Instances
- Figure 10.11 Funding and Investments: Distribution of Amount Invested by Technology
- Figure 10.12 Funding and Investments: Distribution of Amount Invested by Therapeutic Area
- Figure 11.1 Patent Analysis for ZFNs: Distribution by Type of Patent
- Figure 11.2 Patent Analysis for ZFNs: Distribution by Publication Year
- Figure 11.3 Patent Analysis for ZFNs: Distribution by Type of Patent and Publication Year
- Figure 11.4 Patent Analysis for ZFNs: Distribution by Issuing Authority / Patent Offices Involved
- Figure 11.5 Patent Analysis for ZFNs: Distribution by CPC Symbols
- Figure 11.6 Word Cloud Emerging Focus Areas
- Figure 11.7 Patent Analysis for ZFNs: Distribution by Type of Organization
- Figure 11.8 Leading Industry Players of ZFNs: Distribution by Number of Patents
- Figure 11.9 Patent Analysis for ZFNs: Distribution by Patent Age, 2001-2021
- Figure 11.10 Patent Analysis for ZFNs: Benchmarking Patent Analysis
- Figure 11.11 Patent Analysis for ZFNs: Patent Valuation Analysis
- Figure 11.12 Patent Analysis for TALENs: Distribution by Type of Patent
- Figure 11.13 Patent Analysis for TALENs: Distribution by Publication Year
- Figure 11.14 Patent Analysis for TALENs: Distribution by Type of Patent and Publication Year
- Figure 11.15 Patent Analysis for TALENs: Distribution by Issuing Authority / Patent Offices Involved
- Figure 11.16 Patent Analysis for TALENs: Distribution by CPC Symbols
- Figure 11.17 Word Cloud: Emerging Focus Areas
- Figure 11.18 Patent Analysis for TALENs: Distribution by Type of Organization
- Figure 11.19 Leading Industry Players of TALENs: Distribution by Number of Patents
- Figure 11.20 Patent Analysis for TALENs: Distribution by Patent Age, 2001-2021
- Figure 11.21 Patent Analysis for TALENs: Benchmarking Patent Analysis
- Figure 11.22 Patent Analysis for TALENs: Patent Valuation Analysis
- Figure 11.23 Patent Analysis for Meganucleases: Distribution by Type of Patent
- Figure 11.24 Patent Analysis for Meganucleases: Distribution by Publication Year
- Figure 11.25 Patent Analysis for Meganucleases: Distribution by Type of Patent and Publication Year
- Figure 11.26 Patent Analysis for Meganucleases: Distribution by Issuing Authority / Patent Offices Involved
- Figure 11.27 Patent Analysis for Meganucleases: Distribution by CPC Symbols
- Figure 11.28 Word Cloud: Emerging Focus Areas
- Figure 11.29 Patent Analysis for Meganucleases: Distribution by Type of Organization
- Figure 11.30 Leading Industry Players of Meganucleases: Distribution by Number of Patents
- Figure 11.31 Patent Analysis for Meganucleases: Distribution by Patent Age, 2001-2021
- Figure 11.32 Patent Analysis for Meganucleases: Benchmarking Patent Analysis
- Figure 11.33 Patent Analysis for Meganucleases: Patent Valuation Analysis
- Figure 12.1 Key Insights on KOLs: Distribution by Type of Organization
- Figure 12.2 Key Insights on KOLs: Distribution by Region
- Figure 12.3 Key Insights on KOLs: Distribution by Location of Headquarters
- Figure 12.4 Key Insights on KOLs: Distribution by Current Organization
- Figure 12.5 Leading KOLs by Roots Analysis Proprietary Scores
- Figure 12.6 Key Insights on KOLs
- Figure 13.1 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Therapeutic Approach (In vivo / Ex vivo)
- Figure 13.2 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source
- Figure 13.3 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Cell Type
- Figure 13.4 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source and Cell Type
- Figure 13.5 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Target Gene
- Figure 13.6 CRISPR / Cas based Therapeutics Clinical Pipeline: Distribution by Delivery Vehicle Used and Therapeutic Approach
- Figure 13.7 CRISPR / Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Phase of Development
- Figure 13.8 CRISPR / Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Area
- Figure 13.9 CRISPR / Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Technology Used
- Figure 13.10 CRISPR / Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Approach (In vivo / Ex vivo)
- Figure 13.11 CRISPR / Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Delivery Vehicle Used
- Figure 13.12 Most Active Players: Distribution by Number of Drugs
- Figure 13.13 CRISPR based Therapeutics Developers: Distribution by Year of Establishment
- Figure 13.14 CRISPR / Cas based Therapeutics Developers: Distribution by Company Size
- Figure 13.15 CRISPR / Cas based Therapeutics Developers: Distribution by Geographical Location
- Figure 13.16 Logo Landscape of CRISPR / Cas based Therapeutics Developers: Distribution by Size and Phase of Development
- Figure 14.1 Licensing Agreements: Distribution of Financial Components
- Figure 14.2 Technology Licensing Deals: Payment Structure
- Figure 14.3 Gene Editing Technologies: Global Market Opportunity, 2021-2035
- Figure 14.4 Gene Editing Technologies: Distribution by Type of Payment
- Figure 14.5 Gene Editing Technologies: Distribution by Geography, 2021 and 2035
- Figure 14.6 Gene Editing Technologies: Market Opportunity in North America, 2021-2035
- Figure 14.7 Gene Editing Technologies: Market by Upfront Payment in North America, 2021-2035
- Figure 14.8 Gene Editing Technologies: Market by Milestone Payment in North America, 2021-2035
- Figure 14.9 Gene Editing Technologies: Market Opportunity in Europe, 2021-2035
- Figure 14.10 Gene Editing Technologies: Market by Upfront Payment in Europe, 2021-2035
- Figure 14.11 Gene Editing Technologies: Market by Milestone Payment in Europe, 2021-2035
- Figure 14.12 Gene Editing Technologies: Market Opportunity in Asia-Pacific and RoW, 2021-2035
- Figure 14.13 Gene Editing Technologies: Market by Upfront Payment in Asia-Pacific and RoW, 2021-2035
- Figure 14.14 Gene Editing Technologies: Market by Milestone Payment in Asia-Pacific and RoW, 2021-2035
- LIST OF TABLES
- Table 4.1 ZFN based Therapies: Clinical Pipeline
- Table 4.2 TALEN based Therapies: Clinical Pipeline
- Table 4.3 Meganucleases based Therapies: Clinical Pipeline
- Table 4.4 Gene Editing Therapies: List of Developers
- Table 4.5 Gene Editing Technologies: List of Developers
- Table 6.1 List of Clinical Trials, till 2021
- Table 7.1 List of Publications, 2016-2021
- Table 8.1 List of Academic Grants, till 2021
- Table 9.1 List of Partnerships and Collaborations, till 2021
- Table 10.1 List of Funding Instances, till 2021
- Table 11.1 List of Patents, 2013-2021
- Table 12.1 List of KOLs
- Table 13.1 CRISPR / Cas based Therapeutics: Clinical Pipeline
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
